Oncology Institute - CW22 | 10-Q: FY2025 Q1 Revenue: USD 104.41 M

Revenue: As of FY2025 Q1, the actual value is USD 104.41 M.

EPS: As of FY2025 Q1, the actual value is USD -0.21.

Patient Services Segment

• Revenue: $53,068 for the three months ended March 31, 2025, compared to $52,453 for the same period in 2024, representing a 1.2% increase.
• Direct Costs: $47,080 for the three months ended March 31, 2025, compared to $49,497 for the same period in 2024, representing a 4.9% decrease.
• Operating Income: $4,515 for the three months ended March 31, 2025, compared to $1,723 for the same period in 2024.

Dispensary Segment

• Revenue: $49,293 for the three months ended March 31, 2025, compared to $39,679 for the same period in 2024, representing a 24.2% increase.
• Direct Costs: $39,863 for the three months ended March 31, 2025, compared to $32,809 for the same period in 2024, representing a 21.5% increase.
• Operating Income: $9,398 for the three months ended March 31, 2025, compared to $6,839 for the same period in 2024.

Clinical Trials & Other Segment

• Revenue: $2,045 for the three months ended March 31, 2025, compared to $2,534 for the same period in 2024, representing a 19.3% decrease.
• Direct Costs: $214 for the three months ended March 31, 2025, compared to $391 for the same period in 2024, representing a 45.3% decrease.
• Operating Income: $1,774 for the three months ended March 31, 2025, compared to $2,088 for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: -$4,988 for the three months ended March 31, 2025, compared to -$15,883 for the same period in 2024.
• Net Cash Used in Investing Activities: -$202 for the three months ended March 31, 2025, compared to $19,388 provided for the same period in 2024.
• Net Cash Used in Financing Activities: -$4,740 for the three months ended March 31, 2025, compared to -$938 for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: The company has implemented initiatives to reduce costs and more effectively manage working capital, resulting in an 11% reduction in SG&A expenses compared to the prior year same quarter.
• Non-Core Business: The company entered into a Research Services Agreement with Helios CR, Inc., effective May 5, 2025, where the Clinical Trials segment will be operated by Helios under a profit-sharing arrangement.